Cowden Syndrome Market Research Report - Global Forecast till 2027

Global Cowden Syndrome Market Research Report: By Site (Breast, Thyroid, Colorectal, Kidney, Skin), Treatment (Genetic Testing, Chemotherapy, Targeted Therapy, Surgery & Radiation Therapy, Hormone Therapy), End User (Hospital & Clinics) - Forecast till 2027

ID: MRFR/MED/3660-HCR | | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2018-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario:


Cowden syndrome is an inherited condition, which is characterized by multiple, noncancerous growths on various parts of the body. People with the syndrome usually have a large head, benign tumors of the hair follicle, and white papules with a smooth surface in the mouth. The major cause of the syndrome is still unknown, however, genetic factors are considered as a major factor for the market growth. Over 100 types of cancers have been identified. According to cancer research UK, in 2012, globally over 14.1 million of new cancer cases were registered, which is expected to increase continuously in the coming future. According to a study, it is observed that in 99% of the patients suffering from this syndrome shows various symptoms such as breast carcinoma, colorectal polyposis, conjunctival hamartoma, generalized hyperkeratosis, goiter, and others. Because of deteriorating lifestyle due to alcoholism and smoking, there is a continued rise in the incidence of cancer. The global Cowden syndrome market is majorly driven by the increasing prevalence of Cowden syndrome across the globe. Due to lack of treatment, governments of various countries have started supporting the manufacturers for research and development. Additionally, increasing government support for research & development, rising healthcare expenditure, and changing lifestyle have fuelled the market growth. Many types of treatment are available in the market, however, all the treatment show some or other side effects on the body. Side effects of the treatment and the high cost of the medicines may slow the growth of the market during the forecasted period.


The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.


Intended Audience



  • Pharmaceutical Companies

  • Government and private research companies

  • Research and Development (R&D) Companies

  • Drug Manufacturers and Suppliers

  • Medical Research Laboratories


 


Figure 1- Market Synopsis of Global Cowden Syndrome Market Research, by Treatment 2016 (%)
Cowden Syndrome Market


Sources: WHO, cancer research UK, American Cancer Society


Segmentation


The global Cowden syndrome market is segmented on the basis of site, treatment and end users.


On the basis of the site, the market is segmented into the breast, thyroid, endometrium (uterus), colorectal, kidney, skin (melanoma), and others.


On the basis of the treatment, the market is categorized into genetic testing, chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.


On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.


Regional Analysis


The Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer. Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market. Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.


Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support. India and China are expected to lead the market in this region.


On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa Cowden syndrome market. Kuwait, Qatar, Oman, and South Arabia holds the major share of the Middle East market. However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.


Market Assessment


Cowden Syndrome Market 2017


Sources- WHO, cancer research UK, American Cancer Society


Key Players in Global Cowden Syndrome Market


Some of key the players in the market are Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.)



TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Cowden Syndrome Market, By Site

6.1 Introduction

6.2 Breast

Market Estimates & Forecast, 2020-2027

6.3 Thyroid

Market Estimates & Forecast, 2020-2027

6.4 Endometrium

Market Estimates & Forecast, 2020-2027

6.5 Colorectal

Market Estimates & Forecast, 2020-2027

6.6 Kidney

Market Estimates & Forecast, 2020-2027

6.7 Skin

Market Estimates & Forecast, 2020-2027.

6.8 Others

Chapter 7. Global Cowden Syndrome Market, By Treatment

7.1 Introduction

7.2 Genetic Testing

7.3 Chemotherapy

Market Estimates & Forecast, 2020-2027

7.3.1 Anthracyclines

7.3.2 Taxanes

7.3.3 Antimetabolites

7.3.4 Alkylating Agents

7.4 Surgery & Radiation Treatment

Market Estimates & Forecast, 2020-2027

7.5 Targeted Treatment

Market Estimates & Forecast, 2020-2027

7.5.1 Monoclonal Antibodies

7.5.2 Tyrosine Kinase Inhibitors

7.6 Hormone Treatment

Market Estimates & Forecast, 2020-2027

7.7 Biologic Treatment

Market Estimates & Forecast, 2020-2027

7.5 Other

Chapter 8 Global Cowden Syndrome Market, By End User

8.1 Introduction

8.2 Hospital & Clinics

Market Estimates & Forecast, 2020-2027

8.3 Ambulatory Care Centers

Market Estimates & Forecast, 2020-2027

8.4 Others

Chapter 9. Global Cowden Syndrome Market, By Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest Of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic Of Korea

9.4.6 Rest Of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest Of The Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Novartis AG

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 GlaxoSmithKline Plc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bayer AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Amgen, Inc.

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Bristol-Myers Squibb Company

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.6 Eli Lilly And Company

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 F. Hoffmann-La Roche Ltd.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs Of The Market

12.2 Key Companies To Watch

12.3 Prediction Of Pharmaceutical Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Cowden Syndrome Industry Synopsis, 2020-2027

Table 2 Global Cowden Syndrome Market Estimates And Forecast, 2020-2027, (USD Million)

Table 3 Global Cowden Syndrome Market By Region, 2020-2027, (USD Million)

Table 4 Global Cowden Syndrome Market By Site, 2020-2027, (USD Million)

Table 5 Global Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 6 Global Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 7 North America Cowden Syndrome Market By Site, 2020-2027, (USD Million)

Table 8 North America Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 9 North America Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 10 US Market By Site, 2020-2027, (USD Million)

Table 11 US Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 12 US Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 13 Canada Market By Site, 2020-2027, (USD Million)

Table 14 Canada Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 15 Canada Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 16 South America Market By Site, 2020-2027, (USD Million)

Table 17 South America Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 18 South America Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 19 Europe Market By Site, 2020-2027, (USD Million)

Table 20 Europe Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 21 Europe Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 22 Western Europe Market By Site, 2020-2027, (USD Million)

Table 23 Western Europe Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 25 Eastern Europe Market By Site, 2020-2027, (USD Million)

Table 26 Eastern Europe Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 28 Asia Pacific Market By Site, 2020-2027, (USD Million)

Table 29 Asia Pacific Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

Table 31 Middle East & Africa Market By Site, 2020-2027, (USD Million)

Table 32 Middle East & Africa Cowden Syndrome Market By Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Cowden Syndrome Market By End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Global Cowden Syndrome Market

Figure 3 Segmentation Market Dynamics For Global Cowden Syndrome Market

Figure 4 Global Cowden Syndrome Market Share, By Type 2020

Figure 5 Global Cowden Syndrome Market Share, By Treatment 2020

Figure 6 Global Cowden Syndrome Market Share, By End Users, 2020

Figure 7 Global Cowden Syndrome Market Share, By Region, 2020

Figure 8 North America Cowden Syndrome Market Share, By Country, 2020

Figure 9 Europe Cowden Syndrome Market Share, By Country, 2020

Figure 10 Asia Pacific Cowden Syndrome Market Share, By Country, 2020

Figure 11 Middle East & Africa Cowden Syndrome Market Share, By Country, 2020

Figure 12 Global Cowden Syndrome Market: Company Share Analysis, 2020 (%)

Figure 13 Novartis AG: Key Financials

Figure 14 Novartis AG: Segmental Revenue

Figure 15 Novartis AG: Geographical Revenue

Figure 16 GlaxoSmithKline Plc..: Key Financials

Figure 17 GlaxoSmithKline Plc..: Segmental Revenue

Figure 18 GlaxoSmithKline Plc..: Geographical Revenue

Figure 19 Bayer AG: Key Financials

Figure 20 Bayer AG: Segmental Revenue

Figure 21 Bayer AG: Geographical Revenue

Figure 22 Amgen, Inc.: Key Financials

Figure 23 Amgen, Inc.: Segmental Revenue

Figure 24 Amgen, Inc.: Geographical Revenue

Figure 25 Bristol-Myers Squibb Company: Key Financials

Figure 26 Bristol-Myers Squibb Company: Segmental Revenue

Figure 27 Bristol-Myers Squibb Company: Geographical Revenue

Figure 28 F. Hoffmann-La Roche Ltd.: Key Financials

Figure 29 F. Hoffmann-La Roche Ltd.: Segmental Revenue

Figure 30 F. Hoffmann-La Roche Ltd.: Geographical Revenue

Figure 31 AstraZeneca Plc.: Key Financials

Figure 32 AstraZeneca Plc.: Segmental Revenue

Figure 33 AstraZeneca Plc.: Geographical Revenue